Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological pharmaceuticals based on its Israel-patented microencapsulation delivery system. The company is headquartered in Ness Ziona, Israel.
| Revenue (TTM) | $1.79M |
| Gross Profit (TTM) | $-14.03M |
| EBITDA | $-17.69M |
| Operating Margin | -704.00% |
| Return on Equity | -40.80% |
| Return on Assets | -23.90% |
| Revenue/Share (TTM) | $0.61 |
| Book Value | $14.69 |
| Price-to-Book | 4.10 |
| Price-to-Sales (TTM) | 121.93 |
| EV/Revenue | 83.68 |
| EV/EBITDA | 0.23 |
| Quarterly Earnings Growth (YoY) | 487.60% |
| Quarterly Revenue Growth (YoY) | -96.60% |
| Shares Outstanding | $3.27M |
| Float | 489,000 |
| % Insiders | 59.61% |
| % Institutions | 43.05% |
Volatility is currently expanding
SolGel Technologies (SLGL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome Top-line results remain on track for late November 2026 NESS ZIONA, Israel, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.
NESS ZIONA, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.84.
Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044 Sol-Gel completed an oversubscribed underwritten offering, raising gross proceeds of approximately $33.1 million from leading healthcare specialist investors Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in the fourth quarter of 2026 Sol-Gel signed an exclusive license agreement with Sun Pharmaceutical Industries Ltd. for the commercialization of TWYNEO® in India NESS ZIONA, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SLGL and any ticker you trade — then tracks every position and per-strategy win rate.
